Released Nov 13, 2023, before the open
10-Q filed Nov 13, 2023, 44 days after period end · 0001576885-23-000062
Q3 2023 · 10-Q
Revenue—
Net Income-$12.96M-$12.96M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.24-$0.24 N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$16,039,000N/M
Operating Cash Flowderived-$12,905,000N/M
Free Cash Flowderived-$12,912,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | -$12.96M | -$10.71M | -$3.90M | -$2.49M |
| EPS Diluted | -$0.24 | -$0.26 | -$0.10 | -$5.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR